TITLE OF CASE STUDY: HISTORY: 1937- Ranbaxy was founded by Ranjit Singh and Dr. Gurbaksh Singh in Amritsar.1952- Bhaii Mohan Singh joined the company as a partner.1961- First manufacturing plant in Okhla.1969- First real breakthrough came with calmpose.1973- Ranbaxy goes public.1977- Ranbaxy first joint venture in Lagos ( Nigeria).1983- A modern dosage forms faility at Dewas (MP) in India.1990- Ranbaxy got its first US Patent, for doxycycline.1993- Dr Parvinder Singh became CEO of Ranbaxy.1995- Acquisition of Ohm Laboratories of US.1998- Ranbaxy enters USA, world’s largest pharma market with products under its own name.1999- Devinder Singh Brar was appointed as CEO and managing Director.2000- Ranbaxy forays into Brazil, the largest pharmaceutical market in South America.2003- Ranbaxy receives The Economic Times award for Corporate Excellencefor The company ofthe year 2002-2003.2004-Ranbaxy acquired the generics business of RPG Aventies Life Sciences in france to enterEuropean market.2008- Daiichi-sankyo acquired over 51% stake in Ranbaxy Laboratories Ltd.2014- Acquired by Sunpharma.INDUSTRY:The Pharamaceutical industry is part of the healthcare sector that deals with medications. The industrycompromises different subfields pertaining to the development, production and marketing of medications. The Pharmaceutical industry has made a great deal of progress over the last decade due to a research –oriented approach that has improved technologies, developed infrastructures, and increased research in thefield of bioscience.The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms ofvalue, as per a report by Equity Master.STRATEGIES OPTED BY RANBAXY: Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organicand inorganic growth routes. Growth is well spread across geographies with focus on emerging markets TheCompany continues to evaluate acquisition opportunities in India, emerging and developed markets tostrengthen its business and competitiveness. Ranbaxy has forayed into high growth potential segments likeBiologics, Oncology and injectables. These new growth areas will add significant depth to the existing
You've reached the end of your free preview.
Want to read all 4 pages?
Generic drug, Ranbaxy, Ranbaxy Laboratories Ltd, dosage form development